Last reviewed · How we verify
IV Thiotepa
Thiotepa is an alkylating agent that cross-links DNA, disrupting its structure and function, leading to cell death.
Thiotepa is an alkylating agent that cross-links DNA, disrupting its structure and function, leading to cell death. Used for Treatment of malignant pleural effusions, Treatment of ovarian cancer, Treatment of bladder cancer.
At a glance
| Generic name | IV Thiotepa |
|---|---|
| Also known as | Thiotepa |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | alkylating agent |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Thiotepa acts by forming covalent bonds with the N7 position of guanine residues in DNA, causing interstrand and intrastrand cross-links, which inhibit DNA replication and transcription, ultimately resulting in apoptosis.
Approved indications
- Treatment of malignant pleural effusions
- Treatment of ovarian cancer
- Treatment of bladder cancer
Common side effects
- myelosuppression
- nausea and vomiting
- alopecia
Key clinical trials
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases (PHASE1, PHASE2)
- US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies (PHASE1, PHASE2)
- Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) (PHASE2)
- Allo HSCT for High Risk Hemoglobinopathies (PHASE2)
- Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders (PHASE2)
- A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort) (PHASE2)
- TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IV Thiotepa CI brief — competitive landscape report
- IV Thiotepa updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI